v3.26.1
Revenue From Contracts With Customers (Tables)
 6 Months Ended
Mar. 31, 2026
Revenues [Abstract]  
Disaggregation of Revenue The following is revenue by significant business line for the three and six months ended March 31, 2026 and 2025 (in thousands):
Three months ended March 31,Six months ended March 31,
2026202520262025
Significant Business Line
Multiomics$63,704 $63,522 $130,922 $129,820 
Core Products (1)
44,300 47,889 91,907 97,514 
Sample Repository Services36,791 31,927 70,608 63,440 
Total revenue$144,795 $143,338 $293,437 $290,774 
(1)Core Products are Automated Stores, Cryogenic Systems, Automated Sample Tube, Consumables and Instruments and Controlled Rate Thawing Devices.
Remaining Performance Obligations The
following table summarizes when the Company expects to transfer control of the remaining performance obligations and recognize the corresponding revenue (in thousands):
As of March 31, 2026
Less than 1 Year
Greater than 1 Year
Total
Remaining performance obligations$51,323 $13,103 $64,426